From 1 July 2026, Capvaxive®, a 21-valent pneumococcal conjugate vaccine (21vPCV), will be added to the National Immunisation Program (NIP). It will replace Prevenar 13® and Pneumovax 23® for adults.
Capvaxive is recommended and free through the NIP for:
All adults who have previously received a dose of any other pneumococcal vaccine are recommended to receive a dose of Capvaxive® at least 12 months after their last dose.
Do not use Prevenar 13 or Pneumovax 23 beyond 30 June 2026 – stock should be discarded and reported in the State Vaccine Centre system as an ‘expired vaccine’ dated 30 June 2026.
The NSW Immunisation Schedule will be updated to include Capvaxive® for eligible cohorts. Order the new poster for your clinic – indicate size preference (A3 or A4) and quantity required.
Clinical Advice
Health Referral Forms
Error: Contact form not found.
